Search results for "Drugs and Devices"

showing 10 items of 24 documents

Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model.

2012

Background The blood-brain barrier (BBB) represents an insurmountable obstacle for most drugs thus obstructing an effective treatment of many brain diseases. One solution for overcoming this barrier is a transport by binding of these drugs to surface-modified nanoparticles. Especially apolipoprotein E (ApoE) appears to play a major role in the nanoparticle-mediated drug transport across the BBB. However, at present the underlying mechanism is incompletely understood. Methodology/Principal Findings In this study, the uptake of the ApoE-modified nanoparticles into the brain capillary endothelial cells was investigated to differentiate between active and passive uptake mechanism by flow cytome…

Apolipoprotein EDrugs and DevicesDrug Research and DevelopmentLipoproteinsMaterials Sciencelcsh:MedicinePlasma protein bindingBiologyBlood–brain barrierBiochemistryFlow cytometryApolipoproteins EMaterial by AttributeMiceApolipoproteins EDrug Delivery Systemsddc:570Cell Line TumormedicineAnimalsHumansNanotechnologyPharmacokineticsReceptorlcsh:ScienceBiologySerum AlbuminBrain DiseasesMultidisciplinaryMicroscopy Confocalmedicine.diagnostic_testlcsh:RBrainEndothelial CellsProteinsBiological TransportFlow CytometryCell biologymedicine.anatomical_structureBlood-Brain BarrierNanoparticles for drug delivery to the brainLDL receptorNanoparticlesMedicinelcsh:QProtein BindingResearch ArticleBiotechnologyPLoS ONE
researchProduct

Multiple in vitro and in vivo regulatory effects of budesonide in CD4+ T lymphocyte subpopulations of allergic asthmatics.

2012

Abstract BACKGROUND: Increased activation and increased survival of T lymphocytes characterise bronchial asthma. OBJECTIVES: In this study the effect of budesonide on T cell survival, on inducible co-stimulator T cells (ICOS), on Foxp3 and on IL-10 molecules in T lymphocyte sub-populations was assessed. METHODS: Cell survival (by annexin V binding) and ICOS in total lymphocytes, in CD4+/CD25+ and in CD4+/CD25- and Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25-cells was evaluated, by cytofluorimetric analysis, in mild intermittent asthmatics (n = 19) and in controls (n = 15). Allergen induced T lymphocyte proliferation and the in vivo effects of budesonide in mild persistent asthmatics (n =…

BudesonideCD4-Positive T-LymphocytesMalePulmonologylcsh:Medicineimmune system diseasesT-Lymphocyte SubsetsMolecular Cell Biologylcsh:ScienceBudesonidecigarette smoke airway epithelial cells reactive oxygen species.MultidisciplinaryT CellsAllergy and HypersensitivityClinical Pharmacologyhemic and immune systemsForkhead Transcription Factorsrespiratory systemMiddle AgedFlow CytometryBronchodilator AgentsInterleukin-10Interleukin 10MedicineFemalemedicine.drugResearch ArticleAdultDrugs and DevicesAdolescentCell SurvivalImmune CellsImmunologychemical and pharmacologic phenomenaInducible T-Cell Co-Stimulator ProteinImmunomodulationIn vivomedicineHumansInducible T-Cell Co-Stimulator ProteinBiologyAsthmaCell Proliferationbusiness.industrylcsh:RT lymphocytemedicine.diseaseIn vitroAsthmarespiratory tract diseasesApoptosisImmunologylcsh:QClinical ImmunologybusinessCytometryPloS one
researchProduct

Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells.

2011

Breast cancer is the most common cancer and the second leading cause of cancer death in industrialized countries. Systemic treatment of breast cancer is effective at the beginning of therapy. However, after a variable period of time, progression occurs due to therapy resistance. Artesunate, clinically used as anti-malarial agent, has recently revealed remarkable anti-tumor activity offering a role as novel candidate for cancer chemotherapy. We analyzed the anti-tumor effects of artesunate in metastasizing breast carcinoma in vitro and in vivo. Unlike as expected, artesunate induced resistance in highly metastatic human breast cancer cells MDA-MB-231. Likewise acquired resistance led to abol…

Cancer ResearchPhytochemistryPhytopharmacologyCancer TreatmentArtesunateApoptosisElectrophoretic Mobility Shift AssayDrug resistanceNude MiceMetastasischemistry.chemical_compoundMiceMolecular Cell BiologyDrug DiscoveryBreast TumorsBasic Cancer ResearchMedicinebcl-2-Associated X ProteinMultidisciplinaryQRNF-kappa BArtemisininsChemistryOncologyMedicineFemaleMatrix Metalloproteinase 1Breast carcinomamedicine.drugResearch Article570Drugs and DevicesDrug Research and DevelopmentCell SurvivalScienceMice Nude570 Life SciencesBreast NeoplasmsTumor Cell Line610 Medical Sciences MedicineBreast cancerComplementary and Alternative MedicineCell Line TumorAnimalsHumansDoxorubicinBiologyNeoplasm Drug Resistancebusiness.industryCancers and NeoplasmsChemotherapy and Drug Treatmentmedicine.diseaseXenograft Model Antitumor AssaysTranscription Factor AP-1chemistryTumor progressionArtesunateDrug Resistance NeoplasmCancer cellImmunologyEthnopharmacologyCancer researchbusinessPloS one
researchProduct

Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer Drugs

2011

First line chemotherapeutics for brain tumors (malignant gliomas) are alkylating agents such as temozolomide and nimustine. Despite growing knowledge of how these agents work, patients suffering from this malignancy still face a dismal prognosis. Alkylating agents target DNA, forming the killing lesion O(6)-alkylguanine, which is converted into DNA double-strand breaks (DSBs) that trigger apoptosis. Here we assessed whether inhibiting repair of DSBs by homologous recombination (HR) or non-homologous end joining (NHEJ) is a reasonable strategy for sensitizing glioma cells to alkylating agents. For down-regulation of HR in glioma cells, we used an interference RNA (iRNA) approach targeting Ra…

Cancer Treatmentlcsh:MedicineApoptosisToxicologyBiochemistrychemistry.chemical_compoundDrug DiscoveryRNA Small Interferinglcsh:ScienceHomologous RecombinationNeurological TumorsGene knockdownMultidisciplinaryBrain NeoplasmsGliomaFlow CytometryNon-homologous end joiningOncologyPARP inhibitorMedicinemedicine.drugResearch ArticleBiotechnologyDrugs and DevicesDrug Research and DevelopmentDNA damageMorpholinesToxic AgentsOlaparibGliomaCell Line TumormedicineHumansBiologyAntineoplastic Agents AlkylatingProtein Kinase InhibitorsBRCA2 ProteinTemozolomideBase SequenceNimustinelcsh:RCancers and NeoplasmsChemotherapy and Drug Treatmentmedicine.diseasechemistryMicroscopy FluorescenceChromonesCancer researchlcsh:QRad51 RecombinaseDNA DamagePLoS ONE
researchProduct

Validity and reliability of Veloflex to measure active cervical range of motion in asymptomatic and symptomatic subjects

2021

Background Neck pain has a high annual incidence and decreases the cervical active range of motion (ROM). Clinicians use various methods to evaluate cervical range of motion (CROM) that some of them have also been proposed to give instant feedback. Accordingly, this study aimed to examine the validity and reliability of Veloflex (VF) to measure the CROM by comparison with the cervical range of motion (CROM) device, and to examine their test-retest reliability. Methods Thirty-eight healthy and 20 symptomatic participants were evaluated. Cervical flexion-extension, side bending, and rotations were tested in two sessions, first by the CROM and VF and in the second only with the VF. To evaluat…

Cervical range of motionDrugs and Devices030506 rehabilitationmedicine.medical_specialtyAnatomy and PhysiologyConcurrent validityValidity/reliabilitylcsh:MedicineValidityAsymptomaticGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencessymbols.namesake0302 clinical medicinePhysical medicine and rehabilitationMedicineRange of motionAnesthesiology and Pain ManagementOptoelectronic deviceReliability (statistics)business.industryGeneral Neurosciencelcsh:RGeneral MedicineKinesiologyPearson product-moment correlation coefficientOrthopedicsStandard errorsymbolsCervicalmedicine.symptom0305 other medical scienceGeneral Agricultural and Biological SciencesRange of motionbusiness030217 neurology & neurosurgeryPeerJ
researchProduct

Multi frequency phase fluorimetry (MFPF) for oxygen partial pressure measurement: ex vivo validation by polarographic clark-type electrode.

2013

BACKGROUND: Measurement of partial pressure of oxygen (PO2) at high temporal resolution remains a technological challenge. This study introduces a novel PO2 sensing technology based on Multi-Frequency Phase Fluorimetry (MFPF). The aim was to validate MFPF against polarographic Clark-type electrode (CTE) PO2 measurements. METHODOLOGY/PRINCIPAL FINDINGS: MFPF technology was first investigated in N = 8 anaesthetised pigs at FIO2 of 0.21, 0.4, 0.6, 0.8 and 1.0. At each FIO2 level, blood samples were withdrawn and PO2 was measured in vitro with MFPF using two FOXY-AL300 probes immediately followed by CTE measurement. Secondly, MFPF-PO2 readings were compared to CTE in an artificial circulatory s…

Drugs and DevicesAnatomy and PhysiologyMaterials scienceSwinePartial PressurePhase (waves)Analytical chemistrychemistry.chemical_elementlcsh:Medicine610 Medicine & healthBioengineeringCardiovascularCardiovascular SystemOxygenFluorescence spectroscopyMedical Devices03 medical and health sciencesEngineering0302 clinical medicineAnesthesiologyDiagnostic MedicineAnimalsFluorometryddc:610030212 general & internal medicine610 Medicine & healthlcsh:ScienceBiologyBlood gas analysisPolarographyChemical PhysicsAnesthesiology TechnologyMultidisciplinaryPhysicslcsh:RPartial pressureModels TheoreticalOxygenChemistrychemistryElectrodeMedicineHigh temporal resolutionlcsh:QBlood Gas Analysis030217 neurology & neurosurgeryResearch ArticlePLoS ONE
researchProduct

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells

2012

PLoS one 7(7), e40853 (2012). doi:10.1371/journal.pone.0040853

Drugs and DevicesDrug Research and DevelopmentTime Factorsmedicine.drug_classChronic Myeloid LeukemiaIntracellular Spacelcsh:MedicineApoptosisPharmacologyPiperazinesTyrosine-kinase inhibitorHematologic Cancers and Related DisordersCell Line TumorLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesLeukemiasmedicineHumansAnnexin A5Proto-Oncogene Proteins c-abllcsh:ScienceProtein Kinase InhibitorsMyeloproliferative DisordersMultidisciplinaryABLDose-Response Relationship DrugCaspase 3Chemistrylcsh:RBiological activityImatinibHematologyrespiratory tract diseasesDasatinibKineticsPyrimidinesImatinib mesylatePharmacodynamicsBenzamidesImatinib MesylateMedicineATP-Binding Cassette Transporterslcsh:QDrug Screening Assays AntitumorSignal transductionIntracellularResearch ArticleSignal Transductionmedicine.drug
researchProduct

Validity and reliability of the DiCI for the measurement of shoulder flexion and abduction strength in asymptomatic and symptomatic subjects

2021

Background A higher risk of shoulder injury in the athletic and non-athletic population is frequently associated with strength deficits. Therefore, shoulder strength assessment can be clinically useful to identify and to quantify the magnitude of strength deficit. Thus, the aim of this study was to evaluate the validity and reliability of a DiCI (a new hand-held dynamometer) for the measurement of shoulder flexion and abduction strength in asymptomatic and symptomatic subjects. Methods Forty-three recreational athletes (29 males and 14 females; age: 22.1 ± 0.47 years; body mass: 68.7 ± 13.1 kg; height = 173.3 ± 9.7 cm) and 40 symptomatic subjects (28 males and 12 females; age: 49.9 ± 8.1 y…

Drugs and DevicesRelative reliabilitymedicine.medical_specialtyShoulderAnatomy and PhysiologyPopulationValidity/reliabilityValiditySymptomaticShoulder flexionAsymptomaticGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineRheumatologymedicineeducationShoulder injury030222 orthopedicseducation.field_of_studybiologyAthletesbusiness.industryGeneral NeuroscienceR030229 sport sciencesGeneral MedicineKinesiologybiology.organism_classificationHand-held dynamometerOrthopedicsStandard errorPhysical therapyMedicinemedicine.symptomGeneral Agricultural and Biological SciencesbusinessPeerJ
researchProduct

FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia.

2011

Background The contribution of neuroinflammation and specifically brain lymphocyte invasion is increasingly recognised as a substantial pathophysiological mechanism after stroke. FTY720 is a potent treatment for primary neuroinflammatory diseases by inhibiting lymphocyte circulation and brain immigration. Previous studies using transient focal ischemia models showed a protective effect of FTY720 but did only partially characterize the involved pathways. We tested the neuroprotective properties of FTY720 in permanent and transient cortical ischemia and analyzed the underlying neuroimmunological mechanisms. Methodology/Principal Findings FTY720 treatment resulted in substantial reduction of c…

MaleDrugs and DevicesLymphocyteCerebrovascular DiseasesImmunologyNeuroimmunologyIschemialcsh:MedicineBrain EdemaNeuroprotectionProinflammatory cytokineBrain IschemiaBrain ischemiaMiceNeuropharmacologySphingosinemedicine.arteryhemic and lymphatic diseasesmedicineLeukocytesAnimalsLymphoid OrgansLymphocyteslcsh:ScienceStrokeBiologyNeuroinflammationMultidisciplinarybusiness.industryFingolimod HydrochlorideInterleukin-6Tumor Necrosis Factor-alphalcsh:RImmunologic Subspecialtiesmedicine.diseaseMice Inbred C57BLmedicine.anatomical_structureNeurologyPropylene GlycolsImmune SystemImmunologyMiddle cerebral arteryMedicineClinical Immunologylcsh:QbusinessImmunosuppressive AgentsResearch ArticlePLoS ONE
researchProduct

Pre-Infarction Angina and Outcomes in Non-ST-Segment Elevation Myocardial Infarction: Data from the RICO Survey

2012

BACKGROUND: The presence of pre-infarction angina (PIA) has been shown to confer cardioprotection after ST-segment elevation myocardial infarction (STEMI). However, the clinical impact of PIA in non-ST-segment elevation myocardial infarction (NSTEMI) remains to be determined. METHODS AND RESULTS: From the obseRvatoire des Infarctus de Côte d'Or (RICO) survey, 1541 consecutive patients admitted in intensive care unit with a first NSTEMI were included. Patients who experienced chest pain <7 days before the episode leading to admission were defined as having PIA and were compared with patients without PIA. Incidence of in-hospital ventricular arrhythmias (VAs), heart failure and 30-day mortali…

MaleNon-Clinical MedicineMyocardial Infarctionlcsh:MedicineInfarctionCoronary AngiographyCardiovascularChest painAnginaIschemiaST segmentProspective StudiesMyocardial infarctionlcsh:ScienceMultidisciplinaryData CollectionClinical PharmacologyMiddle AgedAnginaPrognosisTreatment OutcomeCardiologyMedicineFemaleFrancemedicine.symptomResearch ArticleDrugs and Devicesmedicine.medical_specialtyCritical CareCardiologyHealth InformaticsCardiovascular PharmacologyAngina PectorisIntensive careInternal medicinemedicineHumansAgedHealth Care Policybusiness.industrylcsh:RArrhythmias Cardiacmedicine.diseaseHealth SurveysHeart failureMultivariate AnalysisMyocardial infarction complicationslcsh:QHealth StatisticsbusinessPLoS ONE
researchProduct